# EDGAR Filing Document

**Accession Number:** 0001427570
**File Stem:** 0001104659-25-076151
**Filing Date:** 2025-8
**Character Count:** 6013
**Document Hash:** 11be100093bf38668a4916c5f62861fa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076151.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001104659-25-076151

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ReShape Lifesciences Inc.
- **CENTRAL INDEX KEY:** 0001427570
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37897
- **FILM NUMBER:** 251201993

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673
- **BUSINESS PHONE:** 949-429-6680

**MAIL ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OBALON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080220

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 7, 2025**

**RESHAPE LIFESCIENCES INC.**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**1-37897** | &nbsp;&nbsp;**1-37897** | &nbsp;&nbsp;**26-1828101** |
| &nbsp;&nbsp; (State or other jurisdiction of incorporation) | &nbsp;&nbsp; (Commission File Number) | &nbsp;&nbsp; (Commission File Number) | &nbsp;&nbsp; (IRS Employer Identification No.) |
| &nbsp;&nbsp; **18 Technology Drive, Suite 110**<br> **Irvine, CA**  | &nbsp;&nbsp; **18 Technology Drive, Suite 110**<br> **Irvine, CA**  | &nbsp;&nbsp; <br> **92618** | &nbsp;&nbsp; <br> **92618** |
| &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) | &nbsp;&nbsp;(Zip Code) |

---

**(949) 429-6680**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) <br>

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) <br>

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) <br>

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value per share | RSLS | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On August 7, 2025, ReShape Lifesciences Inc. (the "Company") reconvened its special meeting of stockholders ("Special Meeting"), which was partially adjourned on July 24, 2025.

The Special Meeting was partially adjourned solely with respect to the voting on Proposal 2, the proposal to approve the sale of substantially all of the Company's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (the "Asset Sale"), and Proposal 3, the proposal to approve and adopt proposed amendments to the Company's Restated Certificate of Incorporation, as amended, in connection with the Company's proposed merger with Vyome Therapeutics, Inc (the "Merger"), each as described further in the Company's proxy statement for the Special Meeting filed with the Securities and Exchange Commission on June 24, 2025 (the "Proxy Statement").

The final results for Proposal 2 and Proposal 3, each as set forth in the Proxy Statement, are as follows:

Proposal 2:

The Company's stockholders approved the Asset Sale, as set forth below.

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 1273715 | 26206 | 2305 |

---

Proposal 3:

The Company's stockholders approved and adopted the proposed amendments to Article VI of the Company's Restated Certificate of Incorporation, as amended, a copy of which is attached to the Proxy Statement as Annex D, which will take effect substantially concurrently with the effective time of the Merger, as set forth below.

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 1240191 | 58555 | 3480 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **RESHAPE LIFESCIENCES INC.** | **RESHAPE LIFESCIENCES INC.** |
| By: | /s/ Paul F. Hickey |
|  | Paul F. Hickey |
|  | President and Chief Executive Officer |

---

Dated: August 11, 2025